Incyte Biosciences UK’s Opzelura (ruxolitinib) cream has been approved for reimbursement for eligible patients with non-segmental vitiligo by the National Institute for Health and Care Excellence ...

Commit Biologics, a biotech company pioneering complement system activation, has appointed Thomas Montgomery Andresen as Chief Executive Officer (CEO), effective 16 March 2026. Thomas, a biotech ...

The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...

Patients should never be treated as passive recipients of AI-enabled outputs. The enduring principles of patient-centred research show that it is precisely the active engagement of patients in the ...

There’s a clear gap: output is rising, but engagement isn’t. This often happens because many strategies focus on HCPs’ ...

Medical Affairs is operating at a pivotal moment. Expectations have expanded rapidly – deeper scientific exchange, sharper ...

Johnson & Johnson (J&J) has announced US FDA approval for Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat adults with relapsed or refractory multiple ...

The elected employee representatives will join the Board of Directors after the annual general meeting on 26 March 2026 ...

The Gilead Foundation has announced a $12m investment in 33 community-based organisations across 14 US states and Washington DC through its Community Health Worker (CHW) Comprehensive HIV Prevention ...

Building on proven methodology, STEM AI was developed to provide an even deeper level of insight for organisations looking to use generative AI to further accelerate team performance. Drawing on ...

CNX Therapeutics, a specialty pharmaceutical company, has appointed Erin Federman as a non-executive director, effective from ...

Despite the GenAI fervour, there is an acute need to prepare organisations to understand which specific tools they need and ...